Urine miRNA in nephrotic syndrome

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 308-313

  Szeto, Cheuk Chun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarkers; Chronic kidney disease; Glomerulonephritis; Inflammation; Urinalysis

Indexed keywords

MICRORNA; MICRORNA 10A; MICRORNA 122; MICRORNA 141; MICRORNA 145; MICRORNA 146A; MICRORNA 15; MICRORNA 150; MICRORNA 155; MICRORNA 184; MICRORNA 192; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 27B; MICRORNA 29A; MICRORNA 29B; MICRORNA 30A 5P; MICRORNA 30D; MICRORNA 323B 5P; MICRORNA 375; MICRORNA 424; MICRORNA 429; MICRORNA 638; UNCLASSIFIED DRUG; BIOLOGICAL MARKERS; MICRORNAS;

DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FOCAL GLOMERULOSCLEROSIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINE LEVEL; URINE SEDIMENT; ANIMALS; GENETICS; HUMANS; KIDNEY DISEASES; URINE;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; KIDNEY DISEASES; MICRORNAS;

EID: 84904123077     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.016     Document Type: Review

References (62)

1. Cameron J.S. Nephrotic syndrome in the elderly. Semin Nephrol 1996, 16:319-329.
2. Haas M., Meehan S.M., Karrison T.G., Spargo B.H. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997, 30:621-631.
3. Endre Z.H., Walker R.J., Pickering J.W., et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010, 77:1020-1030.
4. Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004, 116:281-297.
6. Morita K., Han M. Multiple mechanisms are involved in regulating the expression of the developmental timing regulator lin-28 in Caenorhabditis elegans. EMBO J 2006, 25:5794-5804.
7. Chan S.P., Ramaswamy G., Choi E.Y., Slack F.J. Identification of specific let-7 microRNA binding complexes in Caenorhabditis elegans. RNA 2008, 14:2104-2114.
8. Bernstein E., Kim S.Y., Carmell M.A., et al. Dicer is essential for mouse development. Nat Genet 2003, 35:215-217.
9. Bartels C.L., Tsongalis G.J. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009, 55:623-631.
10. Xiao C., Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009, 136:26-36.
11. Tian Z., Greene A.S., Pietrusz J.L., Matus I.R., Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008, 18:404-411.
12. Sun Y., Koo S., White N., et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004, 32:e188.
13. Schena F.P., Serino G., Sallustio F. MicroRNAs in kidney diseases. New promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant 2014 Apr, 29(4):755-763.
14. Saal S., Harvey S.J. MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens 2009, 18:317-323.
15. Wang Q., Wang Y., Minto A.W., et al. MicroRNA-377 is upregulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008, 22:4126-4135.
16. Wang B., Komers R., Carew R., et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012, 23:252-265.
17. Kato M., Zhang J., Wang M., et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibitors of E-box repressors. Proc Natl Acad Sci U S A 2007, 104:3432-3437.
18. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012, 23:458-469.
19. Zhang Z., Luo X., Ding S., et al. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett 2012, 586:20-26.
20. Fu Y., Zhang Y., Wang Z., et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol 2010, 32:581-589.
21. Serino G., Sallustio F., Cox S.N., Pesce F., Schena F.P. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 2012, 23:814-824.
22. Gregory P.A., Bracken C.P., Bert A.G., Goodall G.J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7:3112-3118.
23. Neilson E.G. Mechanisms of disease: fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2006, 2:101-108.
24. Burk U., Schubert J., Wellner U., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589.
25. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
26. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914.
27. Bracken C.P., Gregory P.A., Kolesnikoff N., et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008, 68:7846-7854.
28. Gregory P.A., Bert A.G., Paterson E.L., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
29. Hanke M., Hoefig K., Merz H., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010, 28:655-661.
30. Cortez M.A., Calin G.A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703-711.
31. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
32. Gilad S., Meiri E., Yogev Y., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
33. Luo Y., Wang C., Chen X., et al. Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem 2013, 59:658-666.
34. Li J.Y., Yong T.Y., Michael M.Z., Gleadle J.M. The role of microRNAs in kidney disease. Nephrology (Carlton) 2010, 15:599-608.
35. Melkonyan H.S., Feaver W.J., Meyer E., et al. Transrenal nucleic acids: from proof of principle to clinical tests. Ann N Y Acad Sci 2008, 1137:73-81.
36. Lorenzen J.M., Volkmann I., Fiedler J., et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011, 11:2221-2227.
37. Wang G., Tam L.S., Li E.K., et al. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 2011, 20:493-500.
38. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
39. Wang G., Szeto C.C. Methods of microRNA quantification in urinary sediment. Methods Mol Biol 2013, 1024:211-220.
40. Alvarez M.L., Khosroheidari M., Kanchi Ravi R., DiStefano J.K. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int 2012, 82:1024-1032.
41. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011, 39:7223-7233.
42. Wang G., Tam L.S., Li E.K., et al. Serum and urinary cell free miR-146a and miR-155 in patients with systemic lupus erythematosus. J Rheumatol 2010, 37:2516-2522.
43. Wang G., Kwan B.C., Lai F.M., Chow K.M., Li P.K., Szeto C.C. Urinary sediment miRNA levels in adult nephrotic syndrome. Clin Chim Acta 2013, 418:5-11.
44. Lan Y.F., Chen H.H., Lai P.F., et al. MicroRNA-494 reduces ATF3 expression and promotes AKI. J Am Soc Nephrol 2012, 23:2012-2023.
45. Ichii O., Otsuka S., Sasaki N., Namiki Y., Hashimoto Y., Kon Y. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int 2012, 81:280-292.
46. Szeto C.C., Kwan B.C., Lai K.B., et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Markers 2012, 33:137-144.
47. Wang N., Zhou Y., Jiang L., et al. Urinary microRNA-10a and microRNA-30d serve as novel, sensitive and specific biomarkers for kidney injury. PLoS One 2012, 7:e51140.
48. Glassock R.J. Pathogenesis of membranous nephropathy: a new paradigm in evolution. Contrib Nephrol 2013, 181:131-142.
49. Argyropoulos C., Wang K., McClarty S., et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 2013, 8:e54662.
50. Hou J., Shan Q., Wang T., et al. Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 2007, 282:17114-17122.
51. Wang G., Kwan B.C., Lai F.M., Chow K.M., Kam-Tao Li P., Szeto CCl Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010, 28:79-86.
52. Barutta F., Tricarico M., Corbelli A., et al. Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 2013, 8:e73798.
53. Yang Y., Xiao L., Li J., Kanwar Y.S., Liu F., Sun L. Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses 2013, 81:274-278.
54. Petri M., Orbai A.M., Alarcón G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
55. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004, 65:521-530.
56. Wang G., Tam L.S., Kwan B.C., et al. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol 2012, 31:435-440.
57. Zhou H., Cleary R.C., Bogaert Y.E. Combination of micro-RNA-192 and microRNA-27b from urinary exosomes differentiate between renal tubular damage and glomerular injury. J Am Soc Nephrol 2008, 19:672A.
58. Lu M.M., Leng R.X., Xu W.D., Ye D.Q. Is serum microRNA better specific marker for systemic lupus erythematosus?. Clin Rheumatol 2012, 31:1143-1144.
59. Guan J., Wang G., Tam L.S., et al. Urinary sediment ICAM-1 level in lupus nephritis. Lupus 2012, 21:1190-1195.
60. Chafin C.B., Regna N.L., Hammond S.E., Reilly C.M. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int Immunopharmacol 2013, 17:894-906.
61. Wyatt R.J., Julian B.A. IgA nephropathy. N Engl J Med 2013, 368:2402-2414.
62. Mimura I., Kanki Y., Kodama T., Nangaku M. Revolution of nephrology research by deep sequencing: ChIP-seq and RNA-seq. Kidney Int 2014, 85:31-38.